Search

Your search keyword '"Ruddy, Kathryn J."' showing total 466 results
Start Over Author "Ruddy, Kathryn J." Search Limiters Full Text
466 results on '"Ruddy, Kathryn J."'

1. Advancing the care of individuals with cancer through innovation & technology: Proceedings from the cardiology oncology innovation summit 2020 and 2021

Author

Brown, Sherry-Ann, Beavers, Craig, Bauer, Brenton, Cheng, Richard K, Berman, Generika, Marshall, Catherine H, Guha, Avirup, Jain, Prantesh, Steward, Austin, DeCara, Jeanne M, Olaye, Iredia M, Hansen, Kathryn, Logan, Jim, Bergom, Carmen, Glide-Hurst, Carri, Loh, Irving, Gambril, John Alan, MacLeod, James, Maddula, Ragasnehith, McGranaghan, Peter J, Batra, Akshee, Campbell, Courtney, Hamid, Abdulaziz, Gunturkun, Fatma, Davis, Robert, Jefferies, John, Fradley, Michael, Albert, Katherine, Blaes, Anne, Choudhuri, Indrajit, Ghosh, Arjun K, Ryan, Thomas D, Ezeoke, Ogochukwu, Leedy, Douglas J, Williams, Wadsworth, Roman, Sebastian, Lehmann, Lorenz, Sarkar, Abdullah, Sadler, Diego, Polter, Elizabeth, Ruddy, Kathryn J, Bansal, Neha, Yang, Eric, Patel, Brijesh, Cho, David, Bailey, Alison, Addison, Daniel, Rao, Vijay, Levenson, Joshua E, Itchhaporia, Dipti, Watson, Karol, Gulati, Martha, Williams, Kim, Lloyd-Jones, Donald, Michos, Erin, Gralow, Julie, and Martinez, Hugo

Published
2024

6. A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry

Author

Middha, Pooja, Wang, Xiaoliang, Behrens, Sabine, Bolla, Manjeet K, Wang, Qin, Dennis, Joe, Michailidou, Kyriaki, Ahearn, Thomas U, Andrulis, Irene L, Anton-Culver, Hoda, Arndt, Volker, Aronson, Kristan J, Auer, Paul L, Augustinsson, Annelie, Baert, Thaïs, Freeman, Laura E Beane, Becher, Heiko, Beckmann, Matthias W, Benitez, Javier, Bojesen, Stig E, Brauch, Hiltrud, Brenner, Hermann, Brooks-Wilson, Angela, Campa, Daniele, Canzian, Federico, Carracedo, Angel, Castelao, Jose E, Chanock, Stephen J, Chenevix-Trench, Georgia, Cordina-Duverger, Emilie, Couch, Fergus J, Cox, Angela, Cross, Simon S, Czene, Kamila, Dossus, Laure, Dugué, Pierre-Antoine, Eliassen, A Heather, Eriksson, Mikael, Evans, D Gareth, Fasching, Peter A, Figueroa, Jonine D, Fletcher, Olivia, Flyger, Henrik, Gabrielson, Marike, Gago-Dominguez, Manuela, Giles, Graham G, González-Neira, Anna, Grassmann, Felix, Grundy, Anne, Guénel, Pascal, Haiman, Christopher A, Håkansson, Niclas, Hall, Per, Hamann, Ute, Hankinson, Susan E, Harkness, Elaine F, Holleczek, Bernd, Hoppe, Reiner, Hopper, John L, Houlston, Richard S, Howell, Anthony, Hunter, David J, Ingvar, Christian, Isaksson, Karolin, Jernström, Helena, John, Esther M, Jones, Michael E, Kaaks, Rudolf, Keeman, Renske, Kitahara, Cari M, Ko, Yon-Dschun, Koutros, Stella, Kurian, Allison W, Lacey, James V, Lambrechts, Diether, Larson, Nicole L, Larsson, Susanna, Le Marchand, Loic, Lejbkowicz, Flavio, Li, Shuai, Linet, Martha, Lissowska, Jolanta, Martinez, Maria Elena, Maurer, Tabea, Mulligan, Anna Marie, Mulot, Claire, Murphy, Rachel A, Newman, William G, Nielsen, Sune F, Nordestgaard, Børge G, Norman, Aaron, O’Brien, Katie M, Olson, Janet E, Patel, Alpa V, Prentice, Ross, Rees-Punia, Erika, Rennert, Gad, Rhenius, Valerie, Ruddy, Kathryn J, and Sandler, Dale P

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer Genomics, Human Genome, Estrogen, Cancer, Women's Health, Genetics, Prevention, Aging, Breast Cancer, 2.1 Biological and endogenous factors, Adult, Female, Humans, Gene-Environment Interaction, Genetic Predisposition to Disease, Breast Neoplasms, Bayes Theorem, Genome-Wide Association Study, Risk Factors, Polymorphism, Single Nucleotide, Case-Control Studies, Breast cancer, Gene-environment interactions, Genetic epidemiology, European ancestry, CTS Consortium, ABCTB Investigators, kConFab Investigators, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundGenome-wide studies of gene-environment interactions (G×E) may identify variants associated with disease risk in conjunction with lifestyle/environmental exposures. We conducted a genome-wide G×E analysis of ~ 7.6 million common variants and seven lifestyle/environmental risk factors for breast cancer risk overall and for estrogen receptor positive (ER +) breast cancer.MethodsAnalyses were conducted using 72,285 breast cancer cases and 80,354 controls of European ancestry from the Breast Cancer Association Consortium. Gene-environment interactions were evaluated using standard unconditional logistic regression models and likelihood ratio tests for breast cancer risk overall and for ER + breast cancer. Bayesian False Discovery Probability was employed to assess the noteworthiness of each SNP-risk factor pairs.ResultsAssuming a 1 × 10-5 prior probability of a true association for each SNP-risk factor pairs and a Bayesian False Discovery Probability

Published
2023

7. NCCN Guidelines® Insights: Survivorship, Version 1.2022.

Author

Sanft, Tara, Day, Andrew, Peterson, Lindsay, Rodriguez, M Alma, Ansbaugh, Shannon, Armenian, Saro, Baker, K Scott, Ballinger, Tarah, Broderick, Gregory, Demark-Wahnefried, Wendy, Dickinson, Kristin, Fairman, Nathan Paul, Friedman, Debra L, Goldman, Mindy, Henry, Norah Lynn, Hill-Kayser, Christine, Hudson, Melissa, Khakpour, Nazanin, Koura, Divya, McDonough, Allison L, Melisko, Michelle, Mooney, Kathi, Moore, Halle C F, Moryl, Natalie, Neuman, Heather, O'Connor, Tracey, Overholser, Linda, Paskett, Electra D, Patel, Chirayu, Pirl, William, Porpiglia, Andrea, Ruddy, Kathryn J, Schapira, Lidia, Shockney, Lillie, Smith, Sophia, Syrjala, Karen L, Tevaarwerk, Amye, Yang, Eric H, Zee, Phyllis, McMillian, Nicole R, and Freedman-Cass, Deborah A

Abstract

The NCCN Guidelines for Survivorship are intended to help healthcare professionals who work with survivors to ensure that the survivors' complex and varied needs are addressed. The NCCN Guidelines provide screening, evaluation, and treatment recommendations for the consequences of adult-onset cancer and its treatment; recommendations to help promote physical activity, weight management, and immunizations in survivors; and a framework for care coordination. This article summarizes updates to the NCCN Guidelines pertaining to preventive health for cancer survivors, including recommendations about alcohol consumption and vaccinations.

Published
2022

10. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry

Author

Mueller, Stefanie H., Lai, Alvina G., Valkovskaya, Maria, Michailidou, Kyriaki, Bolla, Manjeet K., Wang, Qin, Dennis, Joe, Lush, Michael, Abu-Ful, Zomoruda, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Arndt, Volker, Aronson, Kristan J., Augustinsson, Annelie, Baert, Thais, Freeman, Laura E. Beane, Beckmann, Matthias W., Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Blomqvist, Carl, Bogdanova, Natalia V., Bojesen, Stig E., Bonanni, Bernardo, Brenner, Hermann, Brucker, Sara Y., Buys, Saundra S., Castelao, Jose E., Chan, Tsun L., Chang-Claude, Jenny, Chanock, Stephen J., Choi, Ji-Yeob, Chung, Wendy K., Colonna, Sarah V., Cornelissen, Sten, Couch, Fergus J., Czene, Kamila, Daly, Mary B., Devilee, Peter, Dörk, Thilo, Dossus, Laure, Dwek, Miriam, Eccles, Diana M., Ekici, Arif B., Eliassen, A. Heather, Engel, Christoph, Evans, D. Gareth, Fasching, Peter A., Fletcher, Olivia, Flyger, Henrik, Gago-Dominguez, Manuela, Gao, Yu-Tang, García-Closas, Montserrat, García-Sáenz, José A., Genkinger, Jeanine, Gentry-Maharaj, Aleksandra, Grassmann, Felix, Guénel, Pascal, Gündert, Melanie, Haeberle, Lothar, Hahnen, Eric, Haiman, Christopher A., Håkansson, Niclas, Hall, Per, Harkness, Elaine F., Harrington, Patricia A., Hartikainen, Jaana M., Hartman, Mikael, Hein, Alexander, Ho, Weang-Kee, Hooning, Maartje J., Hoppe, Reiner, Hopper, John L., Houlston, Richard S., Howell, Anthony, Hunter, David J., Huo, Dezheng, Ito, Hidemi, Iwasaki, Motoki, Jakubowska, Anna, Janni, Wolfgang, John, Esther M., Jones, Michael E., Jung, Audrey, Kaaks, Rudolf, Kang, Daehee, Khusnutdinova, Elza K., Kim, Sung-Won, Kitahara, Cari M., Koutros, Stella, Kraft, Peter, Kristensen, Vessela N., Kubelka-Sabit, Katerina, Kurian, Allison W., Kwong, Ava, Lacey, James V., Lambrechts, Diether, Le Marchand, Loic, Li, Jingmei, Linet, Martha, Lo, Wing-Yee, Long, Jirong, Lophatananon, Artitaya, Mannermaa, Arto, Manoochehri, Mehdi, Margolin, Sara, Matsuo, Keitaro, Mavroudis, Dimitrios, Menon, Usha, Muir, Kenneth, Murphy, Rachel A., Nevanlinna, Heli, Newman, William G., Niederacher, Dieter, O’Brien, Katie M., Obi, Nadia, Offit, Kenneth, Olopade, Olufunmilayo I., Olshan, Andrew F., Olsson, Håkan, Park, Sue K., Patel, Alpa V., Patel, Achal, Perou, Charles M., Peto, Julian, Pharoah, Paul D. P., Plaseska-Karanfilska, Dijana, Presneau, Nadege, Rack, Brigitte, Radice, Paolo, Ramachandran, Dhanya, Rashid, Muhammad U., Rennert, Gad, Romero, Atocha, Ruddy, Kathryn J., Ruebner, Matthias, Saloustros, Emmanouil, Sandler, Dale P., Sawyer, Elinor J., Schmidt, Marjanka K., Schmutzler, Rita K., Schneider, Michael O., Scott, Christopher, Shah, Mitul, Sharma, Priyanka, Shen, Chen-Yang, Shu, Xiao-Ou, Simard, Jacques, Surowy, Harald, Tamimi, Rulla M., Tapper, William J., Taylor, Jack A., Teo, Soo Hwang, Teras, Lauren R., Toland, Amanda E., Tollenaar, Rob A. E. M., Torres, Diana, Torres-Mejía, Gabriela, Troester, Melissa A., Truong, Thérèse, Vachon, Celine M., Vijai, Joseph, Weinberg, Clarice R., Wendt, Camilla, Winqvist, Robert, Wolk, Alicja, Wu, Anna H., Yamaji, Taiki, Yang, Xiaohong R., Yu, Jyh-Cherng, Zheng, Wei, Ziogas, Argyrios, Ziv, Elad, Dunning, Alison M., Easton, Douglas F., Hemingway, Harry, Hamann, Ute, and Kuchenbaecker, Karoline B.

Published
2023
Full Text
View/download PDF

12. Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women

Author

Wang, Xiaoliang, Kapoor, Pooja Middha, Auer, Paul L, Dennis, Joe, Dunning, Alison M, Wang, Qin, Lush, Michael, Michailidou, Kyriaki, Bolla, Manjeet K, Aronson, Kristan J, Murphy, Rachel A, Brooks-Wilson, Angela, Lee, Derrick G, Cordina-Duverger, Emilie, Guénel, Pascal, Truong, Thérèse, Mulot, Claire, Teras, Lauren R, Patel, Alpa V, Dossus, Laure, Kaaks, Rudolf, Hoppe, Reiner, Lo, Wing-Yee, Brüning, Thomas, Hamann, Ute, Czene, Kamila, Gabrielson, Marike, Hall, Per, Eriksson, Mikael, Jung, Audrey, Becher, Heiko, Couch, Fergus J, Larson, Nicole L, Olson, Janet E, Ruddy, Kathryn J, Giles, Graham G, MacInnis, Robert J, Southey, Melissa C, Le Marchand, Loic, Wilkens, Lynne R, Haiman, Christopher A, Olsson, Håkan, Augustinsson, Annelie, Krüger, Ute, Wagner, Philippe, Scott, Christopher, Winham, Stacey J, Vachon, Celine M, Perou, Charles M, Olshan, Andrew F, Troester, Melissa A, Hunter, David J, Eliassen, Heather A, Tamimi, Rulla M, Brantley, Kristen, Andrulis, Irene L, Figueroa, Jonine, Chanock, Stephen J, Ahearn, Thomas U, García-Closas, Montserrat, Evans, Gareth D, Newman, William G, van Veen, Elke M, Howell, Anthony, Wolk, Alicja, Håkansson, Niclas, Anton-Culver, Hoda, Ziogas, Argyrios, Jones, Michael E, Orr, Nick, Schoemaker, Minouk J, Swerdlow, Anthony J, Kitahara, Cari M, Linet, Martha, Prentice, Ross L, Easton, Douglas F, Milne, Roger L, Kraft, Peter, Chang-Claude, Jenny, and Lindström, Sara

Subjects
Genetics, Cancer, Aging, Human Genome, Breast Cancer, Prevention, Estrogen, 2.1 Biological and endogenous factors, Aetiology, Breast, Breast Neoplasms, Estrogen Replacement Therapy, Female, Hormone Replacement Therapy, Humans, Male, Menopause, Risk Factors
Abstract

Use of menopausal hormone therapy (MHT) is associated with increased risk for breast cancer. However, the relevant mechanisms and its interaction with genetic variants are not fully understood. We conducted a genome-wide interaction analysis between MHT use and genetic variants for breast cancer risk in 27,585 cases and 34,785 controls from 26 observational studies. All women were post-menopausal and of European ancestry. Multivariable logistic regression models were used to test for multiplicative interactions between genetic variants and current MHT use. We considered interaction p-values

Published
2022

13. Secondary Breast Cancer Sociodemographic Characteristics and Survival by Age Group

Author

Sauder, Candice AM, Li, Qian, Bold, Richard J, Ruddy, Kathryn J, and Keegan, Theresa HM

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Aging, Breast Cancer, Adolescent, Adult, Aged, Breast Neoplasms, Female, Humans, Mastectomy, Neoplasms, Second Primary, Proportional Hazards Models, Registries, Young Adult, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundSecondary cancers account for 16% of all new cancer diagnoses, with breast cancer (BC) the most common secondary cancer. We have shown that secondary BC has unique characteristics and decreased survival compared with primary BC in adolescent and young adults (AYA; 15-39 years old). However, older BC populations are less well studied.MethodsFemales (age ≥ 15 years) diagnosed with primary BC during 1991-2015 (n = 377,167) and enrolled in the California Cancer Registry were compared with those with secondary BC (n = 37,625) by age (15-39, 40-64, ≥ 65 years). We examined BC-specific survival (BCSS) accounting for other causes of death as a competing risk using multivariable Cox proportional hazards regression.ResultsMost secondary BC patients were of older age (15-39, n = 777; 40-64, n = 15,848; ≥ 65, n = 21,000). Compared with primary BC treatment, secondary BCs were more often treated with mastectomy and less often with chemotherapy and/or radiation. BCSS was shorter in secondary BC patients than primary BC patients, but the survival difference between secondary and primary BC diminished with age [15-39 hazard ratio (HR): 2.09, 95% confidence interval (CI) 1.83-2.39; 40-64 HR: 1.51; 95% CI 1.44-1.58; ≥ 65 HR: 1.14; 95% CI 1.10-1.19]. Survival differences were most pronounced in women with hormone receptor positive disease and Hispanic and Asian/Pacific Islanders 40-64 years of age.ConclusionsWhen BC is diagnosed following a prior cancer of any organ site, BCSS is worse than when compared with patients for whom BC is the primary diagnosis, suggesting that we may need to tailor our treatments for women with secondary BC.

Published
2021

15. Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea.

Author

Ruddy, Kathryn J, Schaid, Daniel J, Batzler, Anthony, Cecchini, Reena S, Partridge, Ann H, Norman, Aaron, Fehrenbacher, Louis, Stewart, Elizabeth A, Trabuco, Emanuel, Ginsburg, Elizabeth, Couch, Fergus J, Fasching, Peter A, Vachon, Celine, and Ganz, Patricia A

Subjects
Aging, Cancer, Clinical Research, Adult, Amenorrhea, Anti-Mullerian Hormone, Antineoplastic Agents, Biomarkers, Breast Neoplasms, Chemotherapy, Adjuvant, Female, Humans, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Antimullerian hormone (AMH) is a promising biomarker for ovarian reserve. In this study, we assessed AMH before and 1 year after initiation of adjuvant chemotherapy on National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology B-47 in female participants aged 42 years and younger (median age = 39 years). At baseline, median AMH was 1.2 ng/mL; 13 (4.7%) values were less than 0.1 ng/mL (the threshold for detectable levels, in the perimenopause and menopause range), and 57 values (20.6%) were less than 0.5 ng/mL. At 1 year, 215 (77.6%) were less than 0.1 ng/mL, and 264 (95.3%) were less than 0.5 ng/mL. Postchemotherapy menses were reported by 46.2% of participants. Multivariable logistic regression found that the odds of having postchemotherapy menses increased with younger age, higher body mass index, and higher prechemotherapy AMH, but not by trastuzumab administration or by the choice of chemotherapy (doxorubicin-cyclophosphamide followed by paclitaxel vs docetaxel-cyclophosphamide). We conclude that higher prechemotherapy AMH predicts a lower risk of chemotherapy-induced amenorrhea and that AMH 1 year after chemotherapy initiation is not informative in this setting because it is likely to be very low.

Published
2021

16. Genome-Wide Interaction Analysis of Menopausal Hormone Therapy Use and Breast Cancer Risk Among 62,370 Women

Author

Wang, Xiaoliang, Kapoor, Pooja Middha, Auer, Paul L, Dennis, Joe, Dunning, Alison M, Wang, Qin, Lush, Michael, Michailidou, Kyriaki, Bolla, Manjeet K, Aronson, Kristan J, Murphy, Rachel A, Brooks-Wilson, Angela, Lee, Derrick G, Cordina-Duverger, Emilie, Guénel, Pascal, Truong, Thérèse, Mulot, Claire, Teras, Lauren R, Patel, Alpa V, Dossus, Laure, Kaaks, Rudolf, Hoppe, Reiner, Lo, Wing-Yee, Brüning, Thomas, Hamann, Ute, Czene, Kamila, Gabrielson, Marike, Hall, Per, Eriksson, Mikael, Jung, Audrey, Becher, Heiko, Couch, Fergus J, Larson, Nicole L, Olson, Janet E, Ruddy, Kathryn J, Giles, Graham G, MacInnis, Robert J, Southey, Melissa C, Marchand, Loic Le, Wilkens, Lynne R, Haiman, Christopher A, Olsson, Håkan, Augustinsson, Annelie, Krüger, Ute, Wagner, Philippe, Scott, Christopher, Winham, Stacey J, Vachon, Celine M, Perou, Charles M, Olshan, Andrew F, Troester, Melissa A, Hunter, David J, Eliassen, A Heather, Tamimi, Rulla M, Brantley, Kristen, Andrulis, Irene L, Figueroa, Jonine, Chanock, Stephen J, Ahearn, Thomas U, García-Closas, Montserrat, Evans, Gareth D, Newman, William G, Veen, Elke M van, Howell, Anthony, Wolk, Alicja, Håkansson, Niclas, Anton-Culver, Hoda, Ziogas, Argyrios, Jones, Michael E, Orr, Nick, Schoemaker, Minouk J, Swerdlow, Anthony J, Kitahara, Cari M, Linet, Martha, Prentice, Ross L, Easton, Douglas F, Milne, Roger L, Kraft, Peter, Chang-Claude, Jenny, and Lindström, Sara

Subjects
Cancer, Prevention, Breast Cancer, Genetics, Human Genome, Aging, Estrogen, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being
Abstract

Abstract Background: Use of menopausal hormone therapy (MHT) is associated with increased risk for breast cancer. However, the relevant mechanisms and its interaction with genetic variants are not fully understood. Methods: We conducted a genome-wide interaction analysis between MHT use and genetic variants for breast cancer risk in 27,585 cases and 34,785 controls from 26 observational studies. All women were post-menopausal and of European ancestry. Multivariable logistic regression models were used to test for multiplicative interactions between genetic variants and current MHT use. We considered interaction p-values

Published
2021

17. Survivorship, Version 1.2021.

Author

Tevaarwerk, Amye, Denlinger, Crystal S, Sanft, Tara, Ansbaugh, Shannon M, Armenian, Saro, Baker, K Scott, Broderick, Gregory, Day, Andrew, Demark-Wahnefried, Wendy, Dickinson, Kristin, Friedman, Debra L, Ganz, Patricia, Goldman, Mindy, Henry, Norah Lynn, Hill-Kayser, Christine, Hudson, Melissa, Khakpour, Nazanin, Koura, Divya, McDonough, Allison L, Melisko, Michelle, Mooney, Kathi, Moore, Halle CF, Moryl, Natalie, Moslehi, Javid J, O'Connor, Tracey, Overholser, Linda, Paskett, Electra D, Patel, Chirayu, Peterson, Lindsay, Pirl, William, Rodriguez, M Alma, Ruddy, Kathryn J, Schapira, Lidia, Shockney, Lillie, Smith, Sophia, Syrjala, Karen L, Zee, Phyllis, McMillian, Nicole R, and Freedman-Cass, Deborah A

Subjects
Health Services and Systems, Nursing, Health Sciences, Cancer, Rehabilitation, Prevention, Management of diseases and conditions, 7.1 Individual care needs, Good Health and Well Being, Adult, Cancer Survivors, Humans, Mass Screening, Neoplasms, Survivors, Survivorship, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

The NCCN Guidelines for Survivorship are intended to help healthcare professionals working with cancer survivors to ensure that each survivor's complex and varied needs are addressed. The Guidelines provide screening, evaluation, and treatment recommendations for consequences of adult-onset cancer and its treatment; recommendations to help promote healthful lifestyle behaviors, weight management, and immunizations in survivors; and a framework for care coordination. This article summarizes the recommendations regarding employment and return to work for cancer survivors that were added in the 2021 version of the NCCN Guidelines.

Published
2021

18. Long-term outcomes of intraoperatively-placed applicator brachytherapy for rapid completion of breast conserving treatment: An analysis of a prospective registry data

Author

Kim, Haeyoung, Hieken, Tina J., Abraha, Feven, Jakub, James W., Corbin, Kimberly S., Furutani, Keith M., Boughey, Judy C., Stish, Bradley J., Deufel, Christopher L., Degnim, Amy C., Shumway, Dean A., Ahmed, Safia K., Piltin, Mara A., Sandhu, Nicole P., Conners, Amy L., Ruddy, Kathryn J., Mutter, Robert W., and Park, Sean S.

Published
2023
Full Text
View/download PDF

19. Follow-up care for breast cancer survivors

Author

Ruddy, Kathryn J, Herrin, Jeph, Sangaralingham, Lindsey, Freedman, Rachel A, Jemal, Ahmedin, Haddad, Tufia C, Allen, Summer V, Hieken, Tina, Boughey, Judy C, Ganz, Patricia A, Havyer, Rachel D, and Shah, Nilay D

Subjects
Rehabilitation, Breast Cancer, Cancer, Aging, Health Services, Clinical Research, Prevention, 7.3 Management and decision making, Management of diseases and conditions, Aftercare, Breast Neoplasms, Cancer Survivors, Disease Management, Female, Humans, Practice Guidelines as Topic, Public Health Surveillance, Registries, Retrospective Studies, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Breast cancer survivorship guidelines recommend at least annual follow-up visits, yet the degree to which this occurs in clinical practice is uncertain. Claims data from a US commercial insurance database (OptumLabs) were used to identify women treated with curative intent surgery for newly diagnosed breast cancer between 2006 and 2014. In 25 035 women, median follow-up was 3 years. In the second year after surgery, 9.6% of the patients did not visit a primary care provider, an oncologist, or a surgeon (guideline-nonadherent). The guideline-nonadherent proportion increased from 7.8% in women diagnosed in 2006 to 12.2% in those diagnosed in 2014 (two-sided Wald P

Published
2020

23. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial

Author

Barroso-Sousa, Romualdo, Tarantino, Paolo, Tayob, Nabihah, Dang, Chau, Yardley, Denise A., Isakoff, Steven J., Valero, Vicente, Faggen, Meredith, Mulvey, Therese, Bose, Ron, Hu, Jiani, Weckstein, Douglas, Wolff, Antonio C., Reeder-Hayes, Katherine, Rugo, Hope S., Ramaswamy, Bhuvaneswari, Zuckerman, Dan, Hart, Lowell, Gadi, Vijayakrishna K., Constantine, Michael, Cheng, Kit, Briccetti, Frederick, Schneider, Bryan, Garrett, Audrey Merrill, Marcom, Kelly, Albain, Kathy, DeFusco, Patricia, Tung, Nadine, Ardman, Blair, Nanda, Rita, Jankowitz, Rachel C., Rimawi, Mothaffar, Abramson, Vandana, Pohlmann, Paula R., Van Poznak, Catherine, Forero-Torres, Andres, Liu, Minetta, Ruddy, Kathryn J., Zheng, Yue, Rosenberg, Shoshana M., Gelber, Richard D., Trippa, Lorenzo, Barry, William, DeMeo, Michelle, Burstein, Harold, Partridge, Ann, Winer, Eric P., Krop, Ian, and Tolaney, Sara M.

Published
2022
Full Text
View/download PDF

24. Towards defining morphologic parameters of normal parous and nulliparous breast tissues by artificial intelligence

Author

Ogony, Joshua, de Bel, Thomas, Radisky, Derek C., Kachergus, Jennifer, Thompson, E. Aubrey, Degnim, Amy C., Ruddy, Kathryn J., Hilton, Tracy, Stallings-Mann, Melody, Vachon, Celine, Hoskin, Tanya L., Heckman, Michael G., Vierkant, Robert A., White, Launia J., Moore, Raymond M., Carter, Jodi, Jensen, Matthew, Pacheco-Spann, Laura, Henry, Jill E., Storniolo, Anna Maria, Winham, Stacey J., van der Laak, Jeroen, and Sherman, Mark E.

Published
2022
Full Text
View/download PDF

26. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer

Author

Guzmán-Arocho, Yaileen D., Rosenberg, Shoshana M., Garber, Judy E., Vardeh, Hilde, Poorvu, Philip D., Ruddy, Kathryn J., Kirkner, Gregory, Snow, Craig, Tamimi, Rulla M., Peppercorn, Jeffrey, Schapira, Lidia, Borges, Virginia F., Come, Steven E., Brachtel, Elena F., Marotti, Jonathan D., Warner, Ellen, Partridge, Ann H., and Collins, Laura C.

Published
2022
Full Text
View/download PDF

27. Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens

Author

Leal, Alexis D, Van Houten, Holly, Sangaralingham, Lindsey, Freedman, Rachel A, Jemal, Ahmedin, Neuman, Heather B, Haddad, Tufia C, Mutter, Robert W, Keegan, Theresa HM, Mougalian, Sarah S, Loprinzi, Charles L, Gross, Cary P, Shah, Nilay, and Ruddy, Kathryn J

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Breast Cancer, Health Services, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cancer Survivors, Chemotherapy, Adjuvant, Cohort Studies, Cyclophosphamide, Docetaxel, Doxorubicin, Female, Humans, Insurance Claim Review, Lymph Node Excision, Mastectomy, Middle Aged, Office Visits, Paclitaxel, Breast neoplasms, Follow-up, Health care use, Outpatient, Toxicity, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundTreatment-related toxicity can vary substantially between chemotherapy regimens. In this study we evaluated the frequency of outpatient office visits among a cohort of early stage breast cancer survivors after completion of 4 different adjuvant chemotherapy regimens to better understand how differences in toxicities between regimens might affect health care use.Materials and methodsWe analyzed administrative claims data from a US commercial insurance database (OptumLabs) to identify women who received adjuvant doxorubicin/cyclophosphamide (AC), AC followed or preceded by docetaxel or paclitaxel (AC-T), AC concurrent with docetaxel or paclitaxel (TAC), or docetaxel/cyclophosphamide (TC) between 2008 and 2014. We compared mean numbers of visits per patient (adjusted for age, race/ethnicity, region, year, surgery type, radiation, chronic conditions, and previous hospitalizations) across the different regimens (TC = reference) for 12 months, starting 4 months after the end of chemotherapy.ResultsIn 6247 eligible patients, the mean adjusted number of outpatient visits per patient was significantly higher in patients who received AC-T (8.1) or TAC (7.3) than TC (6.5) or AC (6.0; P < .001 for comparisons of AC-T and TAC with TC), primarily because of differences in Medical Oncology visits. Approximately 40% did not see a primary care provider at all during this time frame.ConclusionsAC-T and TAC are associated with more subsequent outpatient visits than TC. Visits to primary care providers are infrequent during the year after completion of chemotherapy.

Published
2018

29. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

Author

Baselga, José, Morales, Serafin M, Awada, Ahmad, Blum, Joanne L, Tan, Antoinette R, Ewertz, Marianne, Cortes, Javier, Moy, Beverly, Ruddy, Kathryn J, Haddad, Tufia, Ciruelos, Eva M, Vuylsteke, Peter, Ebbinghaus, Scot, Im, Ellie, Eaton, Lamar, Pathiraja, Kumudu, Gause, Christine, Mauro, David, Jones, Mary Beth, and Rugo, Hope S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Estrogen, Patient Safety, Clinical Research, Cancer, Breast Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Androstadienes, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Aromatase Inhibitors, Breast Neoplasms, Disease-Free Survival, Female, Humans, Middle Aged, Protein Kinase Inhibitors, Receptors, Estrogen, Sirolimus, Stomatitis, Ridaforolimus, mTOR, Dalotuzumab, IGF1R, Breast cancer, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeCombining the mTOR inhibitor ridaforolimus and the anti-IGFR antibody dalotuzumab demonstrated antitumor activity, including partial responses, in estrogen receptor (ER)-positive advanced breast cancer, especially in high proliferation tumors (Ki67 > 15%).MethodsThis randomized, multicenter, international, phase II study enrolled postmenopausal women with advanced ER-positive breast cancer previously treated with a nonsteroidal aromatase inhibitor (NCT01234857). Patients were randomized to either oral ridaforolimus 30 mg daily for 5 of 7 days (once daily [qd] × 5 days/week) plus intravenous dalotuzumab 10 mg/kg/week or oral exemestane 25 mg/day, and stratified by Ki67 status. Due to a high incidence of stomatitis in the ridaforolimus-dalotuzumab group, two sequential, nonrandomized, reduced-dose cohorts were explored with ridaforolimus 20 and 10 mg qd × 5 days/week. The primary endpoint was progression-free survival (PFS).ResultsMedian PFS was 21.4 weeks for ridaforolimus 30 mg qd × 5 days/week plus dalotuzumab 10 mg/kg (n = 29) and 24.3 weeks for exemestane (n = 33; hazard ratio = 1.00; P = 0.5). Overall survival and objective response rates were similar between treatment arms. The incidence of drug-related, nonserious, and serious adverse events was higher with ridaforolimus/dalotuzumab (any ridaforolimus dose) than with exemestane. Lowering the ridaforolimus dose reduced the incidence of grade 3 stomatitis, but overall toxicity remained higher than acceptable at all doses without improved efficacy.ConclusionsThe combination of ridaforolimus plus dalotuzumab was no more effective than exemestane in patients with advanced ER-positive breast cancer, and the incidence of adverse events was higher. Therefore, the combination is not being further pursued.

Published
2017

30. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

Author

Silvestri, Valentina, Barrowdale, Daniel, Mulligan, Anna Marie, Neuhausen, Susan L, Fox, Stephen, Karlan, Beth Y, Mitchell, Gillian, James, Paul, Thull, Darcy L, Zorn, Kristin K, Carter, Natalie J, Nathanson, Katherine L, Domchek, Susan M, Rebbeck, Timothy R, Ramus, Susan J, Nussbaum, Robert L, Olopade, Olufunmilayo I, Rantala, Johanna, Yoon, Sook-Yee, Caligo, Maria A, Spugnesi, Laura, Bojesen, Anders, Pedersen, Inge Sokilde, Thomassen, Mads, Jensen, Uffe Birk, Toland, Amanda Ewart, Senter, Leigha, Andrulis, Irene L, Glendon, Gord, Hulick, Peter J, Imyanitov, Evgeny N, Greene, Mark H, Mai, Phuong L, Singer, Christian F, Rappaport-Fuerhauser, Christine, Kramer, Gero, Vijai, Joseph, Offit, Kenneth, Robson, Mark, Lincoln, Anne, Jacobs, Lauren, Machackova, Eva, Foretova, Lenka, Navratilova, Marie, Vasickova, Petra, Couch, Fergus J, Hallberg, Emily, Ruddy, Kathryn J, Sharma, Priyanka, Kim, Sung-Won, kConFab Investigators, Teixeira, Manuel R, Pinto, Pedro, Montagna, Marco, Matricardi, Laura, Arason, Adalgeir, Johannsson, Oskar Th, Barkardottir, Rosa B, Jakubowska, Anna, Lubinski, Jan, Izquierdo, Angel, Pujana, Miguel Angel, Balmaña, Judith, Diez, Orland, Ivady, Gabriella, Papp, Janos, Olah, Edith, Kwong, Ava, Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Nevanlinna, Heli, Aittomäki, Kristiina, Perez Segura, Pedro, Caldes, Trinidad, Van Maerken, Tom, Poppe, Bruce, Claes, Kathleen BM, Isaacs, Claudine, Elan, Camille, Lasset, Christine, Stoppa-Lyonnet, Dominique, Barjhoux, Laure, Belotti, Muriel, Meindl, Alfons, Gehrig, Andrea, Sutter, Christian, Engel, Christoph, Niederacher, Dieter, Steinemann, Doris, Hahnen, Eric, Kast, Karin, Arnold, Norbert, Varon-Mateeva, Raymonda, Wand, Dorothea, Godwin, Andrew K, Evans, D Gareth, Frost, Debra, Perkins, Jo, Adlard, Julian, Izatt, Louise, and Platte, Radka

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Cancer, 2.1 Biological and endogenous factors, Aetiology, Adult, Aged, BRCA1 Protein, BRCA2 Protein, Breast Neoplasms, Breast Neoplasms, Male, Female, Genetic Predisposition to Disease, Humans, Male, Middle Aged, Mutation, Neoplasm Staging, Polymorphism, Single Nucleotide, Male breast cancer, BRCA1/2, Pathology, Histologic grade, Genotype-phenotype correlations, kConFab Investigators, Hereditary Breast and Ovarian Cancer Research Group Netherlands, EMBRACE, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundBRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs).MethodsWe characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database.ResultsAmong BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10(-5)) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor-positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15-21.80] and progesterone receptor-positive (OR 5.04; 95 % CI 3.17-8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10(-12)).ConclusionsOn the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.

Published
2016

31. International Pooled Analysis of Leisure-Time Physical Activity and Premenopausal Breast Cancer in Women From 19 Cohorts

Author

Epi Kanker, JC onderzoeksprogramma Cancer, Cancer, Timmins, Iain R, Jones, Michael E, O'Brien, Katie M, Adami, Hans-Olov, Aune, Dagfinn, Baglietto, Laura, Bertrand, Kimberly A, Brantley, Kristen D, Chen, Yu, Clague DeHart, Jessica, Clendenen, Tess V, Dossus, Laure, Eliassen, A Heather, Fletcher, Olivia, Fournier, Agnès, Håkansson, Niclas, Hankinson, Susan E, Houlston, Richard S, Joshu, Corinne E, Kirsh, Victoria A, Kitahara, Cari M, Koh, Woon-Puay, Linet, Martha S, Park, Hannah Lui, Lynch, Brigid M, May, Anne M, Mellemkjær, Lene, Milne, Roger L, Palmer, Julie R, Ricceri, Fulvio, Rohan, Thomas E, Ruddy, Kathryn J, Sánchez, Maria-Jose, Shu, Xiao-Ou, Smith-Byrne, Karl, Steindorf, Karen, Sund, Malin, Vachon, Celine M, Vatten, Lars J, Visvanathan, Kala, Weiderpass, Elisabete, Willett, Walter C, Wolk, Alicja, Yuan, Jian-Min, Zheng, Wei, Nichols, Hazel B, Sandler, Dale P, Swerdlow, Anthony J, Schoemaker, Minouk J, Epi Kanker, JC onderzoeksprogramma Cancer, Cancer, Timmins, Iain R, Jones, Michael E, O'Brien, Katie M, Adami, Hans-Olov, Aune, Dagfinn, Baglietto, Laura, Bertrand, Kimberly A, Brantley, Kristen D, Chen, Yu, Clague DeHart, Jessica, Clendenen, Tess V, Dossus, Laure, Eliassen, A Heather, Fletcher, Olivia, Fournier, Agnès, Håkansson, Niclas, Hankinson, Susan E, Houlston, Richard S, Joshu, Corinne E, Kirsh, Victoria A, Kitahara, Cari M, Koh, Woon-Puay, Linet, Martha S, Park, Hannah Lui, Lynch, Brigid M, May, Anne M, Mellemkjær, Lene, Milne, Roger L, Palmer, Julie R, Ricceri, Fulvio, Rohan, Thomas E, Ruddy, Kathryn J, Sánchez, Maria-Jose, Shu, Xiao-Ou, Smith-Byrne, Karl, Steindorf, Karen, Sund, Malin, Vachon, Celine M, Vatten, Lars J, Visvanathan, Kala, Weiderpass, Elisabete, Willett, Walter C, Wolk, Alicja, Yuan, Jian-Min, Zheng, Wei, Nichols, Hazel B, Sandler, Dale P, Swerdlow, Anthony J, and Schoemaker, Minouk J

Published
2024

32. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy

Author

Hertz, D, Tofthagen, C, Rossi, E, Bernasconi, D, Lim, J, Carlson, M, Sheffield, K, Nekhlyudov, L, Grech, L, Von Ah, D, Mayo, S, Ruddy, K, Chan, A, Alberti, P, Lustberg, M, Tanay, M, Hertz, Daniel L, Tofthagen, Cindy, Rossi, Emanuela, Bernasconi, Davide Paolo, Lim, Jiyoon, Carlson, Martha, Sheffield, Katharine E, Nekhlyudov, Larissa, Grech, Lisa, Von Ah, Diane, Mayo, Samantha J, Ruddy, Kathryn J, Chan, Alexandre, Alberti, Paola, Lustberg, Maryam B, Tanay, Mary, Hertz, D, Tofthagen, C, Rossi, E, Bernasconi, D, Lim, J, Carlson, M, Sheffield, K, Nekhlyudov, L, Grech, L, Von Ah, D, Mayo, S, Ruddy, K, Chan, A, Alberti, P, Lustberg, M, Tanay, M, Hertz, Daniel L, Tofthagen, Cindy, Rossi, Emanuela, Bernasconi, Davide Paolo, Lim, Jiyoon, Carlson, Martha, Sheffield, Katharine E, Nekhlyudov, Larissa, Grech, Lisa, Von Ah, Diane, Mayo, Samantha J, Ruddy, Kathryn J, Chan, Alexandre, Alberti, Paola, Lustberg, Maryam B, and Tanay, Mary

Abstract

Purpose: Clinical practice guidelines recommend altering neurotoxic chemotherapy treatment in patients experiencing intolerable chemotherapy-induced peripheral neuropathy (CIPN). The primary objective of this survey was to understand patient’s perspectives on altering neurotoxic chemotherapy treatment, including their perceptions of the benefits of preventing irreversible CIPN and the risks of reducing treatment efficacy. Methods: A cross-sectional online survey was distributed via social networks to patients who were currently receiving or had previously received neurotoxic chemotherapy for cancer. Survey results were analyzed using descriptive statistics and qualitative analysis. Results: Following data cleaning, 447 participants were included in the analysis. The median age was 57 years, 93% were white, and most were from the UK (53%) or USA (38%). Most participants who were currently or recently treated expected some CIPN symptom resolution (86%), but 45% of those who had completed treatment more than a year ago reported experiencing no symptom resolution. Participants reported that they would discontinue chemotherapy treatment for less severe CIPN if they knew their symptoms would be permanent than if symptoms would disappear after treatment. Most patients stated that the decision to alter chemotherapy or not was usually made collaboratively between the patient and their treating clinician (61%). The most common reason participants were reluctant to talk with their clinician about CIPN was fear that treatment would be altered. Participants noted a need for improved understanding of CIPN symptoms and their permanence, better patient education relating to CIPN prior to and after treatment, and greater clinician understanding and empathy around CIPN. Conclusions: This survey highlights the importance of shared decision-making, including a consideration of both the long-term benefits and risks of altering neurotoxic chemotherapy treatment due to CIPN. Additional wo

Published
2024

34. Advocate-BREAST: advocates and patients' advice to enhance breast cancer care delivery, patient experience and patient centered research by 2025.

Author

O'Sullivan, Ciara C., Larson, Nicole L., Vierkant, Robert A., Smith, Mary Lou, Chauhan, Cynthia, Couch, Fergus J., Olson, Janet E., Loprinzi, Charles L., and Ruddy, Kathryn J.

Subjects
METASTATIC breast cancer, PATIENT experience, PATIENTS' attitudes, BREAST cancer, HOT flashes
Abstract

Purpose: The aims of the Advocate-BREAST project are to study and improve the breast cancer (BC) patient experience through education and patient-centered research. Methods: In December 2021, an electronic REDCap survey was circulated to 6,918 BC survivors (stage 0–4) enrolled in the Mayo Clinic Breast Disease Registry. The questionnaire asked about satisfaction with BC care delivery, and education and support receive(d) regarding BC linked concerns. Patients also ranked Quality Improvement (QI) proposals. Results: The survey received 2,437 responses. 18% had Ductal Carcinoma in Situ, 81% had early breast cancer (EBC), i.e. stage 1–3, and 2% had metastatic breast cancer (MBC). Mean age was 64 (SD 11.8), and mean time since diagnosis was 93 months (SD 70.2). 69.3% of patients received all care at Mayo Clinic. The overall experience of care was good (> 90%). The main severe symptoms recalled in year 1 were alopecia, eyebrow/eyelash thinning, hot flashes, sexual dysfunction, and cognitive issues. The main concerns recalled were fear of BC recurrence/spread; loved ones coping; fear of dying, and emotional health. Patients were most dissatisfied with information regarding sexual dysfunction, eyebrow/eyelash thinning, peripheral neuropathy, and on side effects of immunotherapy/targeted therapies. Top ranking QI projects were: i) Lifetime access to concise educational resources; ii) Holistic support programs for MBC and iii) Wellness Programs for EBC and MBC. Conclusions: Patients with early and advanced BC desire psychological support, concise educational resources, and holistic care. Implications: Focused research and QI initiatives in these areas will improve the BC patient experience. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women Aged ≥80 Years.

Author

O'Sullivan, Ciara C., Vierkant, Robert A., Larson, Nicole L., Smith, Mary Lou, Chauhan, Cynthia, Couch, Fergus J., Olson, Janet E., D'Andre, Stacy, Jatoi, Aminah, and Ruddy, Kathryn J.

Subjects
BREAST tumor treatment, PATIENT education, PSYCHOLOGICAL distress, RESEARCH funding, BREAST tumors, CLINICAL medicine research, MEDICAL care, INTERVIEWING, DECISION making, DESCRIPTIVE statistics, CANCER patients, SYMPTOMS, PATIENT-centered care, SURVEYS, WOMEN'S health, NEEDS assessment, PATIENT satisfaction, SELF advocacy
Abstract

Simple Summary: The high-level aims of the Advocate-BREAST initiative are to study and improve the overall experience of patients with breast cancer (BC) through education, shared decision making, and patient-centered clinical trials. Advocate-BREAST80+ is a survey substudy that specifically focused on the unique needs and perspectives of BC patients aged ≥80 years. Although patients aged ≥80 years experienced less anxiety and symptom-related distress compared with younger patients, they were significantly less satisfied with information regarding short and long term side effects of BC therapies, as well as the management of same. Older patients were significantly less likely to have participated in a clinical trial or be open to considering this option in future. Future research should address unique educational needs and barriers to research participation in older BC patients. Focused interviews could assist with better comprehension of the lived experience of these patients, given the smaller number of BC patients ≥80 years in many available databases. Background: There are limited evidence-based data to guide treatment recommendations for breast cancer (BC) patients ≥80 years (P80+). Identifying and addressing unmet needs are critical. Aims: Advocate-BREAST80+ compared the needs of P80+ vs. patients < 80 years (P80−). Methods: In 12/2021, a REDCap survey was electronically circulated to 6918 persons enrolled in the Mayo Clinic Breast Disease Registry. The survey asked about concerns and satisfaction with multiple aspects of BC care. Results: Overall, 2437 participants responded (35% response rate); 202 (8.3%) were P80+. P80+ were less likely to undergo local regional and systemic therapies vs. P80− (p < 0.01). Notably, P80+ were significantly less satisfied with information about the short and long-term side effects of BC therapies and managing toxicities. P80+ were also less likely to have participated in a clinical trial (p < 0.001) or to want to do so in the future (p = 0.0001). Conclusions: Although P80+ experienced less anxiety and symptom-related distress compared with P80−, they were significantly less satisfied with information regarding the side effects of BC therapies and their management. P80+ were significantly less likely to have participated in a clinical trial or be open to considering this option. Future studies should address educational needs pertaining to side effects and barriers to research participation in P80+. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. A Multiomics, Molecular Atlas of Breast Cancer Survivors.

Author

Bauer, Brent A., Schmidt, Caleb M., Ruddy, Kathryn J., Olson, Janet E., Meydan, Cem, Schmidt, Julian C., Smith, Sheena Y., Couch, Fergus J., Earls, John C., Price, Nathan D., Dudley, Joel T., Mason, Christopher E., Zhang, Bodi, Phipps, Stephen M., and Schmidt, Michael A.

Subjects
OMEGA-3 fatty acids, BREAST cancer, FATTY acids, MULTIOMICS, CANCER survivors
Abstract

Breast cancer imposes a significant burden globally. While the survival rate is steadily improving, much remains to be elucidated. This observational, single time point, multiomic study utilizing genomics, proteomics, targeted and untargeted metabolomics, and metagenomics in a breast cancer survivor (BCS) and age-matched healthy control cohort (N = 100) provides deep molecular phenotyping of breast cancer survivors. In this study, the BCS cohort had significantly higher polygenic risk scores for breast cancer than the control group. Carnitine and hexanoyl carnitine were significantly different. Several bile acid and fatty acid metabolites were significantly dissimilar, most notably the Omega-3 Index (O3I) (significantly lower in BCS). Proteomic and metagenomic analyses identified group and pathway differences, which warrant further investigation. The database built from this study contributes a wealth of data on breast cancer survivorship where there has been a paucity, affording the ability to identify patterns and novel insights that can drive new hypotheses and inform future research. Expansion of this database in the treatment-naïve, newly diagnosed, controlling for treatment confounders, and through the disease progression, can be leveraged to profile and contextualize breast cancer and breast cancer survivorship, potentially leading to the development of new strategies to combat this disease and improve the quality of life for its victims. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Advancing the care of individuals with cancer through innovation & technology: Proceedings from the cardiology oncology innovation summit 2020 and 2021

Author

Brown, Sherry-Ann, primary, Beavers, Craig, additional, Bauer, Brenton, additional, Cheng, Richard K., additional, Berman, Generika, additional, Marshall, Catherine H., additional, Guha, Avirup, additional, Jain, Prantesh, additional, Steward, Austin, additional, DeCara, Jeanne M., additional, Olaye, Iredia M., additional, Hansen, Kathryn, additional, Logan, Jim, additional, Bergom, Carmen, additional, Glide-Hurst, Carri, additional, Loh, Irving, additional, Gambril, John Alan, additional, MacLeod, James, additional, Maddula, Ragasnehith, additional, McGranaghan, Peter J., additional, Batra, Akshee, additional, Campbell, Courtney, additional, Hamid, Abdulaziz, additional, Gunturkun, Fatma, additional, Davis, Robert, additional, Jefferies, John, additional, Fradley, Michael, additional, Albert, Katherine, additional, Blaes, Anne, additional, Choudhuri, Indrajit, additional, Ghosh, Arjun K., additional, Ryan, Thomas D., additional, Ezeoke, Ogochukwu, additional, Leedy, Douglas J., additional, Williams, Wadsworth, additional, Roman, Sebastian, additional, Lehmann, Lorenz, additional, Sarkar, Abdullah, additional, Sadler, Diego, additional, Polter, Elizabeth, additional, Ruddy, Kathryn J., additional, Bansal, Neha, additional, Yang, Eric, additional, Patel, Brijesh, additional, Cho, David, additional, Bailey, Alison, additional, Addison, Daniel, additional, Rao, Vijay, additional, Levenson, Joshua E., additional, Itchhaporia, Dipti, additional, Watson, Karol, additional, Gulati, Martha, additional, Williams, Kim, additional, Lloyd-Jones, Donald, additional, Michos, Erin, additional, Gralow, Julie, additional, and Martinez, Hugo, additional

Published
2023
Full Text
View/download PDF

41. Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

Author

Bayani, Jane, Poncet, Coralie, Crozier, Cheryl, Neven, Anouk, Piper, Tammy, Cunningham, Carrie, Sobol, Monika, Aebi, Stefan, Benstead, Kim, Bogler, Oliver, Dal Lago, Lissandra, Fraser, Judith, Hilbers, Florentine, Hedenfalk, Ingrid, Korde, Larissa, Linderholm, Barbro, Martens, John, Middleton, Lavinia, Murray, Melissa, Kelly, Catherine, Nilsson, Cecilia, Nowaczyk, Monika, Peeters, Stephanie, Peric, Aleksandra, Porter, Peggy, Schröder, Carolien, Rubio, Isabel T., Ruddy, Kathryn J., van Asperen, Christi, Van Den Weyngaert, Danielle, van Deurzen, Carolien, van Leeuwen-Stok, Elise, Vermeij, Joanna, Winer, Eric, Giordano, Sharon H., Cardoso, Fatima, and Bartlett, John M. S.

Published
2021
Full Text
View/download PDF

42. Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial)

Author

Ruddy, Kathryn J, Guo, Hao, Barry, William, Dang, Chau T, Yardley, Denise A, Moy, Beverly, Marcom, P Kelly, Albain, Kathy S, Rugo, Hope S, Ellis, Matthew J, Shapira, Iuliana, Wolff, Antonio C, Carey, Lisa A, Overmoyer, Beth A, Hudis, Clifford, Krop, Ian E, Burstein, Harold J, Winer, Eric P, Partridge, Ann H, and Tolaney, Sara M

Subjects
Clinical Research, Prevention, Breast Cancer, Aging, Cancer, Contraception/Reproduction, Estrogen, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Amenorrhea, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Clinical Trials, Phase II as Topic, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Grading, Neoplasm Staging, Paclitaxel, Trastuzumab, Tumor Burden, Breast cancer, Chemotherapy, Fertility, Premenopausal, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Chemotherapy-related amenorrhea (CRA) is associated with infertility and menopausal symptoms. Learning how frequently paclitaxel and trastuzumab cause amenorrhea is important. Most other adjuvant breast cancer therapies induce CRA in approximately 50 % of all premenopausal recipients [1]. 410 patients enrolled on the APT Trial, a single-arm phase 2 adjuvant study of 12 weeks of paclitaxel and trastuzumab followed by nine months of trastuzumab monotherapy. Eligible patients had ≤3 cm node-negative HER2 + breast cancers. Premenopausal enrollees were asked to complete menstrual surveys every 3-12 months for 72 months. Women who responded to at least one survey at least 15 months after chemotherapy initiation (and who did not undergo hysterectomy and/or bilateral oophorectomy or receive ovarian suppressing medications prior to 15 months) were included in this analysis. A participant was defined as having amenorrhea in follow-up if her self-reported last menstrual period at last follow-up was greater than 12 months prior to the survey. Among the 64 women in the evaluable population (median age at study entry 44 years, range 27-52 years), the median time between chemotherapy initiation and last menstrual survey was 51 months (range 16-79). 18 of 64 women (28 %, 95 % CI 18-41 %) were amenorrheic at that time point. Amenorrhea rates among premenopausal women treated with adjuvant paclitaxel and trastuzumab for early stage breast cancer appear lower than those seen historically with standard alkylator-based breast cancer regimens. Future studies are needed to understand the impact of this regimen on related issues of fertility and menopausal symptoms.

Published
2015

43. Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer

Author

Ruddy, Kathryn J., Schaid, Daniel J., Partridge, Ann H., Larson, Nicholas B., Batzler, Anthony, Häberle, Lothar, Dittrich, Ralf, Widschwendter, Peter, Fink, Visnja, Bauer, Emanuel, Schwitulla, Judith, Rübner, Matthias, Ekici, Arif B., Aivazova-Fuchs, Viktoria, Stewart, Elizabeth A., Beckmann, Matthias W., Ginsburg, Elizabeth, Wang, Liewei, Weinshilboum, Richard M., Couch, Fergus J., Janni, Wolfgang, Rack, Brigitte, Vachon, Celine, and Fasching, Peter A.

Published
2019
Full Text
View/download PDF

45. Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression

Author

Nishida, Jun, primary, Cristea, Simona, additional, Bodapati, Sudheshna, additional, Puleo, Julieann, additional, Bai, Gali, additional, Patel, Ashka, additional, Hughes, Melissa, additional, Snow, Craig, additional, Borges, Virginia, additional, Ruddy, Kathryn J., additional, Collins, Laura C., additional, Feeney, Anne-Marie, additional, Slowik, Kara, additional, Bossuyt, Veerle, additional, Dillon, Deborah, additional, Lin, Nancy U., additional, Partridge, Ann H., additional, Michor, Franziska, additional, and Polyak, Kornelia, additional

Published
2023
Full Text
View/download PDF

46. Longitudinal cognitive function and brain metabolites in women receiving chemotherapy for stage 1 to 3 breast cancer: Observational study

Author

Beyer, Joana, primary, Couch, Ronan, additional, Ruddy, Kathryn J., additional, Zeydan, Burcu, additional, Tosakulwong, Nirubol, additional, Lesnick, Timothy G., additional, Novotny, Paul J., additional, Kohli, Sadhna, additional, Cerhan, Jane H., additional, Pruthi, Sandhya, additional, Kantarci, Kejal, additional, and Kara, Firat, additional

Published
2023
Full Text
View/download PDF

47. Trends in new and persistent opioid use in older adults with and without cancer

Author

Baum, Laura Van Metre, primary, KC, Madhav, additional, Soulos, Pamela R, additional, Jeffery, Molly M, additional, Ruddy, Kathryn J, additional, Lerro, Catherine C, additional, Lee, Hana, additional, Graham, David J, additional, Rivera, Donna R, additional, Leapman, Michael S, additional, Jairam, Vikram, additional, Dinan, Michaela A, additional, Gross, Cary P, additional, and Park, Henry S, additional

Published
2023
Full Text
View/download PDF

49. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients

Author

Norton, Nadine, Youssef, Bahaaeldin, Hillman, David W., Nassar, Aziza, Geiger, Xochiquetzal J., Necela, Brian M., Liu, Heshan, Ruddy, Kathryn J., Polley, Mei-Yin C., Ingle, James N., Couch, Fergus J., Perez, Edith A., Liu, Minetta C., Carter, Jodi M., Leon-Ferre, Roberto A., Boughey, Judy C., Somers, Elizabeth B., Kalari, Krishna R., Visscher, Daniel W., Goetz, Matthew P., and Knutson, Keith L.

Published
2020
Full Text
View/download PDF

50. Changes in amount and intensity of physical activity over time in breast cancer survivors

Author

Marell, Paulina S, primary, Vierkant, Robert A, additional, Olson, Janet E, additional, Herrmann, Joerg, additional, Larson, Nicole L, additional, Lebrasseur, Nathan K, additional, D’Andre, Stacy D, additional, Ehlers, Diane K, additional, Stan, Daniela L, additional, Cheville, Andrea L, additional, Barksdale, Toure, additional, Loprinzi, Charles L, additional, Couch, Fergus J, additional, and Ruddy, Kathryn J, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results